228 related articles for article (PubMed ID: 26274780)
21. Development of 1,3-diynyl derivatives of noscapine as potent tubulin binding anticancer agents for the management of breast cancer.
Meher RK; Pragyandipta P; Reddy PK; Pedaparti R; Kantevari S; Naik PK
J Biomol Struct Dyn; 2022; 40(23):13136-13153. PubMed ID: 34583618
[TBL] [Abstract][Full Text] [Related]
22. A new antiproliferative noscapine analogue: chemical synthesis and biological evaluation.
Ghaly PE; Abou El-Magd RM; Churchill CD; Tuszynski JA; West FG
Oncotarget; 2016 Jun; 7(26):40518-40530. PubMed ID: 27777381
[TBL] [Abstract][Full Text] [Related]
23. Structural Basis of Noscapine Activation for Tubulin Binding.
Oliva MA; Prota AE; Rodríguez-Salarichs J; Bennani YL; Jiménez-Barbero J; Bargsten K; Canales Á; Steinmetz MO; Díaz JF
J Med Chem; 2020 Aug; 63(15):8495-8501. PubMed ID: 32657585
[TBL] [Abstract][Full Text] [Related]
24. Molecular insight into γ-γ tubulin lateral interactions within the γ-tubulin ring complex (γ-TuRC).
Suri C; Hendrickson TW; Joshi HC; Naik PK
J Comput Aided Mol Des; 2014 Sep; 28(9):961-72. PubMed ID: 25031076
[TBL] [Abstract][Full Text] [Related]
25. Insights into the structure and tubulin-targeted anticancer potential of N-(3-bromobenzyl) noscapine.
Cheriyamundath S; Mahaddalkar T; Reddy Nagireddy PK; Sridhar B; Kantevari S; Lopus M
Pharmacol Rep; 2019 Feb; 71(1):48-53. PubMed ID: 30465924
[TBL] [Abstract][Full Text] [Related]
26. Elucidation of the Tubulin-targeted Mechanism of Action of 9-(3-pyridyl) Noscapine.
Pradhan S; Mahaddalkar T; Choudhary S; Manhcukonda N; Nagireddy PR; Kantevari S; Lopus M
Curr Top Med Chem; 2017; 17(22):2569-2574. PubMed ID: 28056737
[TBL] [Abstract][Full Text] [Related]
27. In silico studies and fluorescence binding assays of potential anti-prion compounds reveal an important binding site for prion inhibition from PrP(C) to PrP(Sc).
Pagadala NS; Perez-Pineiro R; Wishart DS; Tuszynski JA
Eur J Med Chem; 2015 Feb; 91():118-31. PubMed ID: 25042003
[TBL] [Abstract][Full Text] [Related]
28. Determination of noscapine's localization and interaction with the tubulin-α/β heterodimer.
Alisaraie L; Tuszynski JA
Chem Biol Drug Des; 2011 Oct; 78(4):535-46. PubMed ID: 21781284
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
30. Noscapinoids with anti-cancer activity against human acute lymphoblastic leukemia cells (CEM): a three dimensional chemical space pharmacophore modeling and electronic feature analysis.
Naik PK; Santoshi S; Joshi HC
J Mol Model; 2012 Jan; 18(1):307-18. PubMed ID: 21523542
[TBL] [Abstract][Full Text] [Related]
31. Computational design of Tryprostatin-A derivatives as novel αβ-tubulin inhibitors.
Fani N; Bordbar AK; Ghayeb Y; Sepehri S
J Biomol Struct Dyn; 2015; 33(3):471-86. PubMed ID: 24606044
[TBL] [Abstract][Full Text] [Related]
32. Exploring the Origin of Differential Binding Affinities of Human Tubulin Isotypes αβII, αβIII and αβIV for DAMA-Colchicine Using Homology Modelling, Molecular Docking and Molecular Dynamics Simulations.
Kumbhar BV; Borogaon A; Panda D; Kunwar A
PLoS One; 2016; 11(5):e0156048. PubMed ID: 27227832
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the effect of the chiral centers of Taxol on binding to β-tubulin: A docking and molecular dynamics simulation study.
Ghadari R; Alavi FS; Zahedi M
Comput Biol Chem; 2015 Jun; 56():33-40. PubMed ID: 25854803
[TBL] [Abstract][Full Text] [Related]
34. Structural investigations into the binding mode of novel neolignans Cmp10 and Cmp19 microtubule stabilizers by in silico molecular docking, molecular dynamics, and binding free energy calculations.
Tripathi S; Kumar A; Kumar BS; Negi AS; Sharma A
J Biomol Struct Dyn; 2016 Jun; 34(6):1232-40. PubMed ID: 26212016
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, Molecular Docking, Molecular Dynamics Studies, and Biological Evaluation of 4H-Chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylate Derivatives as Potential Antileukemic Agents.
Dolatkhah Z; Javanshir S; Sadr AS; Hosseini J; Sardari S
J Chem Inf Model; 2017 Jun; 57(6):1246-1257. PubMed ID: 28524659
[TBL] [Abstract][Full Text] [Related]
36. Investigation of HDAC8-ligands' intermolecular forces through molecular dynamics simulations: profiling of non-bonding energies to design potential compounds as new anti-cancer agents.
Dewaker V; Srivastava AK; Arora A; Prabhakar YS
J Biomol Struct Dyn; 2021 Aug; 39(13):4726-4751. PubMed ID: 32578494
[TBL] [Abstract][Full Text] [Related]
37. Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.
Bennani YL; Gu W; Canales A; Díaz FJ; Eustace BK; Hoover RR; Jiménez-Barbero J; Nezami A; Wang T
J Med Chem; 2012 Mar; 55(5):1920-5. PubMed ID: 22320354
[TBL] [Abstract][Full Text] [Related]
38. Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics.
Lopus M; Naik PK
Pharmacol Rep; 2015 Feb; 67(1):56-62. PubMed ID: 25560576
[TBL] [Abstract][Full Text] [Related]
39. Second generation benzofuranone ring substituted noscapine analogs: synthesis and biological evaluation.
Mishra RC; Karna P; Gundala SR; Pannu V; Stanton RA; Gupta KK; Robinson MH; Lopus M; Wilson L; Henary M; Aneja R
Biochem Pharmacol; 2011 Jul; 82(2):110-21. PubMed ID: 21501599
[TBL] [Abstract][Full Text] [Related]
40. Docking and molecular dynamics studies of the binding between Peloruside A and tubulin.
Liao SY; Mo GQ; Chen JC; Zheng KC
J Enzyme Inhib Med Chem; 2014 Oct; 29(5):702-9. PubMed ID: 24156744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
